Table 2.
Baseline Characteristics.
| Pt | Age/Sex | Malignancy | Prior therapy | Comorbidities | ICPi regimen (and # of cycles) prior to AIHA |
|---|---|---|---|---|---|
| 1 | 85M | Melanoma | None | MZL (not treated), DM II | Pembro 2mg/kg Q3 weeks (2) |
| 2 | 48M | Melanoma | None | None | Ipi 3mg/kg + nivo 1mg/kg both Q3 weeks (3) |
| 3 | 67F | Melanoma | None | None | Ipi 3mg/kg + nivo 1mg/kg both Q3 weeks (4) |
| 4 | 68M | Melanoma | None | Leukopeniaa | Pembro 2mg/kg/day Q3 weeks (12)b |
| 5 | 18M | Melanoma | None | None | Ipi 3mg/kg +nivo 1mg/kg Q3 weeks (4) |
| 6 | 47M | Melanoma | pINF, IL-2 with TILs and TBI | HTN, HLD | Ipi 3mg/kg Q3 weeks (1) |
| 7 | 59F | NSCLC | Multiple agentsc | MZL (in remission) | Nivo 3mg/kg Q2 weeks (12) |
| 8 | 63F | NSCLC | Carboplatin/paclitaxel with XRT | CLL (not treated), DM II | Nivo 3mg/kg Q2 weeks (4) |
| 9 | 33F | AMLd | FLAG-IDA | None | Nivo 3mg/kg Q2 weeks (1) |
| 10 | 85F | Melanoma | None | DM II, breast cancer | Pembro 2mg/kg Q3 weeks (10) |
| 11 | 69F | Colorectal | Multiple agentse | HTN | Pembro 200mg Q3 weeks (1)f |
| 12 | 67M | Melanoma | None | DVT | Ipi 2mg/kg + nivo 1mg/kg both Q3 weeks (2) |
| 13 | 55M | Melanoma | Multiple agentsg | CLL, ITP | Pembro 2mg/kg Q3 weeks (1) |
| 14 | 71F | NSCLC | None | None | Pembro 200mg Q3 weeks (4) |
Long-standing history of leukopenia of unclear etiology, bone marrow biopsy negative for malignancy and leukopenia believed to be autoimmune in nature.
Received indoximod in combination with ICPi therapy as part of a clinical trial.
R-CHOP, fludarabine (received >3 years prior to development of AIHA), XRT, Auto-SCT for treatment of MZL, cisplatin and etoposide for treatment of NSCLC.
Received nivolumab on a clinical trial after conventional chemotherapy.
5-FU, oxaliplatin, irinotecan, bevacizumab, panitumumab, regorafenib, trifluridine/tipiracil.
Received GVAX and cyclophosphamide in combination with ICPi therapy as part of a clinical trial
Dabrafenib, trametinib for treatment of melanoma, fludarabine (received >3 years prior to development of AIHA), cyclophosphamide, bendamustine, rituximab, obinutuzumab, and ibrutinib for treatment of CLL.
Abbreviations: 5-FU, 5-fluorouracil; AML, acute myelogenous leukemia; Auto-SCT, autologous stem cell transplant; CLL, chronic lymphocytic leukemia; DM II, type II diabetes mellitus; DVT, deep venous thrombosis; FLAG-IDA, fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin; GVAX, granulocyte-macrophage colony-stimulating factor allogeneic cancer vaccine; HLD, hyperlipidemia; HTN, hypertension; ICPi, immune checkpoint inhibitor; IL-2, interleukin 2; Ipi, ipilimumab; ITP, immune thrombocytopenia; MZL, marginal zone lymphoma; nivo, nivolumab; NSCLC, non-small cell lung cancer; Pembro, pembrolizumab; pIFN, pegylated interferon; R-CHOP, rituximab, cyclophosphamide, doxorubicin (Hydroxydaunomycin), vincristine (Oncovin), prednisone; TBI, total body irradiation; TILs, tumor infiltrating lymphocytes; XRT, radiation therapy.